Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | UGT1A1 | P22309 | 1/20 | 1.00 |
| ▸ | SQLE | Q14534 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ICMT | O60725 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geranylgeraniol SCHEMBL127330 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Farnesol SCHEMBL17633996 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL17557239 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL16664300 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4717874 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL23814969 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Farnesol SCHEMBL6422271 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Solanesol SCHEMBL4762223 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Farnesol SCHEMBL7546574 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16664315 | 1.00 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2022-08-09 | — | — | US | disclosed |
| EP-2868658-B1 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2868658-B1 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9828323-B2 | Process for preparation of MK-7 type of vitamin K2 | NATTOPHARMA R & D LTD. (CY) | 2017-11-28 | — | — | US | disclosed |
| US-9828323-B2 | Process for preparation of MK-7 type of vitamin K2 | NATTOPHARMA R & D LTD. (CY) | 2017-11-28 | — | — | US | disclosed |
| US-9464021-B2 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP S (IN) | 2016-10-11 | — | — | US | disclosed |
| US-9464021-B2 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP S (IN) | 2016-10-11 | — | — | US | disclosed |
| US-9464021-B2 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP S (IN) | 2016-10-11 | — | — | US | disclosed |
| US-20150291498-A1 | PROCESS FOR PREPARATION OF MK-7 TYPE OF VITAMIN K2 | NATTOPHARMA R&D LTD (CY) | 2015-10-15 | — | — | US | disclosed |
| US-20150291498-A1 | PROCESS FOR PREPARATION OF MK-7 TYPE OF VITAMIN K2 | NATTOPHARMA R&D LTD (CY) | 2015-10-15 | — | — | US | disclosed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-6288128-B1 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound | EISAI CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| US-6111131-A | SUCH AS 3,7,11,15,19,23,27,31-OCTAMETHYL-2,6,10,14,18,22,26,30-DOTRIACONTAOCTAEN-1 -OL; USEFUL AS PROPHYLACTIC DRUG FOR IMMUNODEFICIENCY DISEASES AND INFECTIOUS DISEASES | EISAI CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| US-5658958-A | β, γ-dihydropolyprenyl alcohol derivatives effective at mitigating stress in animals | EISAI CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0304842-B1 | Isoprenoid derivatives and anti-ulcer agents containing the same | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5280048-A | Antiinfection agent | EISAI CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| US-4906669-A | Isoprenoid derivatives and anti-ulcer agents containing the same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0304842-A2 | Isoprenoid derivatives and anti-ulcer agents containing the same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4624966-A | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound | EISAI CO., LTD. (JP) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291498-A1 | PROCESS FOR PREPARATION OF MK-7 TYPE OF VITAMIN K2 | SIRT7, PROC, F7 | KMT2A 384/4885MAPT 4863/4885MEN1 38/4885 |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | CYBB, NOX1, NOX5 | KMT2A 3330/4885MAPT 3853/4885MEN1 3279/4885 |
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | PROC, VKORC1, VKORC1L1 | KMT2A 1147/4885MAPT 4639/4885MEN1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.